In The News

Five industry leaders provide their perspectives on how these types of studies are evolving and their impact on the research industry.

The future is a connected user experience with automated workflows and transparency to accelerate studies without compromising compliance.

The FDA's draft guidance mandates Diversity Action Plans for phase 3 trials to address past underrepresentation adds complexity for sponsors.

Luke Gelinas and other experts highlight the potential impact FDA's Diversity Action Plan guidance will have on industry.

The clinical trial landscape faces challenges like patient recruitment and workforce shortages, making streamlined technology essential.

Applied Clinical Trials held an expert roundtable event focused on the current state of sustainability in clinical research.

Improving trial feasibility through better collaboration and automation can significantly accelerates timelines and mitigate common issues.

May 29, 2024

Christine Senn highlights the importance of thorough feasibility processes in rare disease trials. The need for diverse site participation and data inputs to improve trial accuracy and efficiency. The role ...

In 2023, the FDA approved 55 new drugs and five gene therapies for rare diseases. Yet, there has been little progress in accelerating development timelines.

Once the FDA’s sIRB mandate is in effect nearly all multisite research conducted in the US will require sIRB review.

As the US continues to grapple with politics and science meeting, the global healthcare sector is already investing in women’s health research.

The National Institutes of Health (NIH) has chosen Advarra as its exclusive single institutional review board (sIRB) for clinical trials.